C18 C19 C20
Conditions
Interventions
Group 1: This non-interventional study is observing a patient population with histologically or cytologically diagnosed colorectal cancer, for which the treatment with Irinotecan LIV Pharma is indica
Sponsors
LIV Pharma GmbH
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: indicated according to SPC • Age: over 18 years • Irinotecan LIV is used in therapy. • A manually signed and dated informed consent is present. • The therapy was chosen independently from possible enrollment
Exclusion criteria
Exclusion criteria: • contraindications to the use of Irinotecan LIV Pharma according to SPC • The current therapy was started more than 12 weeks ago. • The patient is participatiing in a clinical trial • A pregnancy is present or the patient is breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy and Tolerability routine practice. Observational, non-interventional study. In detail: Was therapy completed as planned and what was the response. | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life and aide effects which were not observed so far. QoL will be assessed by FACT-C, Scales of oping with the illness (Trierer Skalen zur Krankheitsbewältigung) TSK and and Hospital Axiety and Depression Scale (HADS). | — |
Countries
Germany
Contacts
Public ContactJan Janssen
Praxis für Innere Medizin,Hämatologie und Onkologie, Notfallmedizin
Outcome results
None listed